Page 3 - Cell Therapy Development News Today

– Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive... | April 12, 2023

Recommendation for approval based on Phase 3 TRANSFORM study, supporting the potential of Breyanzi in earlier lines of therapy in this patient population ... | March 31, 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of lisocabtagene maraleucel for the treatment of select patients with large B-cell lymphoma who relapsed within 12 months from completion of or developed refractory disease to frontline chemoimmunotherapy.

In a Phase III study, a CAR T-cell therapy more than tripled progression-free survival compared with standard care for multiple myeloma.

Topline results were announced from the TRANSCEND CLL 004 trial investigating lisocabtagene maraleucel for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

[215+ Pages Report] The size & share of the Global Gene Synthesis Market is predicted to grow to around 4,021.41 USD Million by 2028 with a compound annual...

Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated its type II variation application for extension of the indication for Breyanzi (lisocabtagene maraleucel) to treat adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL) ...

The Global Gene Synthesis Market size is expected to reach $5. 2 billion by 2027, rising at a market growth of 17. ...

Phase 3 TRANSFORM study shows Breyanzi significantly improved event-free survival (EFS) vs. chemotherapy plus autologous stem cell transplant, with a 65% reduction in risk of EFS events in first disclosure of results presented at ASH 2021Breyanzi showed a manageable safety profile and no new safety signals observed,...

Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.